Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids like non-intoxicating rare cannabinoid delta-9-THCV, at commercial scale for the health and wellness industry.
Excerpt:
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc.(Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug development. With the acquisition long since closed, the end results are starting to bear fruit. The company has already launched B2B sales of the rare cannabinoid cannabidivarin (CBDV) in the U.S. health and wellness sector. This is but a preview of additional product launches that will be introduced to market in the coming quarters.
High up on the priority list is tetrahydrocannabivarin (THCV), a cannabinoid chemical found in cannabis that shares broad similarities in molecular structure to tetrahydrocannabinol THC. Incredibly, the reduction of one sidechain, thereby reducing the molecule by two carbons, producing enough of a differentiated effect that preliminary research suggests that THCV could provide distinctive benefits to consumers—particularly at titrated doses.
